Hero Image

Études cliniques

“Les études cliniques sont la clé des nouvelles connaissances en termes de diagnostic et de traitement des maladies. Nous sommes fiers d’y contribuer en Suisse.”

Klaudia Georgi, Sr. Director Clinical Research MSD Switzerland & Austria

Notre travail en chiffres

46

essais cliniques en cours en Suisse (état 04/2024)

15

médicaments et vaccins premiers de la classe thérapeutique enregistrés en Suisse depuis 2000 (état 04/2024)

147

millions de francs suisses investis dans la recherche depuis 2012 (état: 04/2024)

La recherche clinique de MSD Suisse est coordonnée depuis la filiale de Citybay à Lucerne

Le programme d’études cliniques de MSD en Suisse (état 04/2024)

(publié sur www.clinicaltrials.gov)

Carte: Sites des études cliniques de MSD Suisse (état 04/2024)

Dans le domaine de l'immunologie

Maladie de la peau

MK6194-007 – recruitment open

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Non-Segmental Vitiligo

Study centers: St.Gallen, Zurich


Maladie intestinale

MK7240-001 – recruitment open

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis

Study centers: Bern, St.Gallen, Zurich

 

MK7240-008 – Study in start-up

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn’s Disease

Study centers: Basel, Bern, St.Gallen, Zurich


Dans le domaine de l'infectiologie

VIH

MK-8591-013 – recruitment closed

A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily

Study centers: Basel, Bern, Geneva, Lausanne, Zurich

 

MK-8591A-033 – recruitment closed

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Study centers: Basel, Bern, Geneva, Lugano, St. Gallen, Zurich

 

MK-8591A-051 – recruitment closed

A Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy

Study centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich

 

MK8591A-053 – study in start-up

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Study centers: Basel, Geneva

 

MK-8591A-054 – recruitment closed

A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study

Study centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich


Dans le domaine de la médecine générale

Maladie du foie

MK-6024-013 – recruitment open

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis (NASH)

Study centers:Lugano, St. Gallen, Zurich


Maladie pulmonaire

MK-5475-013 – recruitment open

A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease

Study centers: St.Gallen, Zurich, Basel


Dans le domaine de l'oncologie

Cancer de l’estomac

MK-3475-859/KEYNOTE-859 – recruitment closed

A Phase III, randomized, double-blind clinical study of pembrolizumab (MK 3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma

Study centers: Bellinzona, Zurich

 

MK-9999-U02A – Study in start-up

A Phase 1/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Study centers: Bellinzona, Geneva


Cancer de l'œsophage

MK-3475-06A – recruitment open

A Phase 1/2 Open-Label, Umbrella Platform Design Study of InvestigationalAgents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.

Study centers: Chur, Geneva

 

MK-3475-06B – recruitment open

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B.

Study centers: Chur, Geneva

 

MK-3475-06C – Study in start-up

A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Study centers: Chur, Geneva

 

MK-3475-06D – Study in start-up

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Study centers: Chur, Geneva


Cancer de la tête et du cou

MK-3475-689/KEYNOTE-689 – recruitment closed

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Study centers: Bellinzona, Geneva


Cancer de la vessie

MK-3475-676/KEYNOTE-676 – recruitment open

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Study centers: Basel, Geneva, Zurich


Cancer de l'utérus

MK2870-005 – study in start-up

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy

Study centers: Bern, Bellinzona, Chur, Lausanne, Basel

 

MK2870-020 – Study in start-up

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer

Study centers: Basel, Bern


Cancer du foie

MK-1308A-004 – recruitment closed

A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Coformulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular

Study centers: Bern, Geneva, Lausanne, Zurich

 

MK-3475-937/KEYNOTE-937 – recruitment closed

A phase III adjuvant, randomized, placebo – controlled, double-blinded study, in surgically resected or ablated HCC patients

Study centers: Basel, Bern, Geneva, Lausanne, St. Gallen, Winterthur, Zurich


Cancer du poumon

MK2870-019 – study in start-up

A Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery

Study centers: Lausanne, Fribourg, Frauenfeld, Chur

 

MK-3475-091/KEYNOTE-091 – outsourced – recruitment closed

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Study centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich

 

MK-3475-495/KEYNOTE-495; KeyImPaCT – recruitment closed

KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Study centers: Basel, St. Gallen, Zurich

 

MK-3475-867/KEYNOTE-867 – recruitment closed

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)

Study centers: Geneva

 

MK-3475-B98 – recruitment closed

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy

Study center: St. Gallen

 

MK-7684A-002 – recruitment closed

A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Study center: Bellinzona


Cancer du rein (Carcinome rénal)

MK-6482-011 – recruitment closed

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Study centers: Bellinzona, Chur, Geneva, Zurich


Cancer du sang (Tumeurs malignes hématologiques)

MK-1026-003 – recruitment open

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Study centers: Bellinzona, Bern

 

MK4280A-008 – recruitment open

A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory

Study centers: Bellinzona


Cancer du sein

MK-2870-010 – Study in start-up

An Open-label, Ranomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Study centers: Basel, Thun, Zurich

 

MK-2870-012 – Study in start-up

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery

Study centers: Chur, Fribourg, Geneva, Thun, Zurich


Mélanome

MK-3475-U02A – recruitment open

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – refractory

Study centers: Geneva, Zurich

 

MK-3475-U02B – recruitment open

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – 1st line

Study centers: Geneva, Zurich

 

MK-3475-U02C – recruitment open

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – neoadjuvant

Study centers: Geneva, Zurich

 

MK-3475-U02D – recruitment open

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) – neoadjuvant

Study centers: Geneva, Zurich

 

MK-3475-054 / KEYNOTE-054 – outsourced – recruitment closed

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Study centers: Geneva, St. Gallen, Zurich

 

MK-3475-716/KEYNOTE-716 – recruitment closed

Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Study centers: Bellinzona, Basel, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich

 

MK-7684A-010 – recruitment closed

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK‑7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma

Study centers: St.Gallen, Zurich, Bern, Basel, Lausanne, Geneva, Sion, Bellinzona


Tumeurs solides

MK-0472-001 – recruitment open

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.

Study centers: Geneva, Bellinzona, St. Gallen

 

MK-1084-001 – recruitment open

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

Study centers: Bellinzona, St. Gallen

 

MK-3475-587/KEYNOTE-587 – recruitment closed

Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Study center: Basel, Geneva, Zurich

 

MK-6598-001 – recruitment open

A Phase I, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Study centers: Bellinzona, Geneva, St. Gallen

 

MK-7339-002 – recruitment open

A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Study center: Bellinzona

 

MK-7902-005 – recruitment closed

A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Study centers: Bern, St. Gallen, Zurich


Vers l’aperçu des études en Suisse, rechercher les participants www.kofam.ch

CH-NON-00136, 05/2024